ReviewFrontiers in immunology2025
The new era of immunotherapy for breast cancer: challenges and coping strategies of CAR-T cell therapy.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Combined treatment of TROP‑2 targeted CAR-T and vascular disruptor CBP enhances anti‑tumor activity in triple‑negative breast cancer.Translational oncology · 2026Article
- Harnessing immunity against breast cancer: from checkpoints to cell therapies.Journal of translational medicine · 2026Review
- Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer remains the most prevalent malignant tumor among women globally, with persistently high incidence and mortality rates. Despite the diversity of existing treatment modalities, systemic therapies for advanced, metastatic, and triple-negative breast cancer continue to face significant limitations. Recently, chimeric antigen receptor T (CAR-T) cell therapy has demonstrated considerable success in the treatment of hematological malignancies, offering a novel approach for breast cancer treatment. This paper reviews the primary targets and research advancements of CAR-T cells in breast cancer therapy, while also analyzing current challenges such as immunosuppression within the tumor microenvironment, antigen heterogeneity, obstacles in cell homing, and the limited durability of CAR-T cells. Furthermore, strategies to address these challenges are discussed. Although CAR-T cell therapy for breast cancer is still in the nascent stages of exploration, ongoing technological advancements and in-depth research hold promise for its potential as a novel therapeutic option, thereby offering renewed hope to patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.